Keyword: Enyo Pharma

Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.

Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.

Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.